Skip to main content
Premium Trial:

Request an Annual Quote

Decode's Q2 Revenue Falls 27 Percent as Loss Narrows

NEW YORK (GenomeWeb News) - Decode Genetics today said second-quarter revenues fell by 27 percent as R&D spending grew 10 percent and losses fell 11 percent.
Total receipts for the three months ended June 30 fell to $7.6 million from $10.4 million year over year. The company attributed the decrease in revenue to the conclusion of its diagnostics partnership with Roche in 2006.
R&D spending rose to $14.5 million from $13.2 million year over year. Decode said the rising costs are due to “the advance of our drug development programs, the launch of our first DNA-based tests for gauging individual risk of common diseases, and the acceleration of our gene and target discovery work.”
The company reduced its net loss to $16.2 million from $18.3 million in the year-ago period.
Decode said it had around $137.2 million in cash, cash equivalents, and investments as of June 30.
Company CEO Kari Stefansson said in a statement that Decode ended the quarter with a “strengthened cash position" that it will use to fund further product development.
Stefansson added that the company recently launched DNA-based tests for assessing the risk of type 2 diabetes and the risk of atrial fibrillation and stroke, and said Decode's compound for heart attack treatment and its anti-platelet therapeutic have shown encouraging clinical results.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.